Real-world study of epcoritamab for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diffuse large B-cell lymphoma or follicular lymphoma that has come back or not gotten better after at least two prior treatments.
- Your doctor has already decided to prescribe epcoritamab for you before talking to you about this study.
- You cannot be in another clinical trial that tests a new treatment while in this study.
- You must not have any medical condition that would make epcoritamab unsafe for you, as listed in the drug's safety information in your country.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial compares the drug epcoritamab with a 'watch and wait' approach for people with low-tumor-burden follicular lymphoma who have not had treatment before. It tests whether starting treatment early with epcoritamab can improve outcomes.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.